-
stake in five of its subsidiaries:
Myovant Sciences,
Urovant Sciences,
Enzyvant Therapeutics,
Altavant Sciences, and
Spirovant Sciences,
which now sit...
- in
September 2019 of five
Roivant subsidiaries,
including Urovant and
Enzyvant. In
October 2022,
Sumitomo Pharma announced the
acquisition of all outstanding...
-
pediatric disease voucher and
granted approval of
Rethymic to
Enzyvant Therapeutics, Inc. "
Enzyvant Resubmits Biologics Licensing Application (BLA) to FDA for...
-
cultured postnatal thymus-derived tissue) is a
medication being developed by
Enzyvant Therapeutics Ireland Limited for the
treatment of
congenital athymia (absence...
- 2019,
Roivant sold its
stake in five
subsidiaries (or "vants"),
including Enzyvant, to
Sumitomo Dainippon Pharma;
Ramaswamy made $175
million in
capital gains...
- Rare
pediatric Oxlumo Primary hyperoxaluria type 1
Alnylam Pharmaceuticals 2020 Rare
pediatric Rethymic Congenital athymia Enzyvant Therapeutics 2021...
-
Sumitovant Biopharma Ltd.,
Myovant Sciences, Inc.,
Urovant Sciences, Inc.,
Enzyvant Therapeutics, Inc., and
Sumitomo Pharma Oncology, Inc. to form Sumitomo...
-
hemoglobin Sickle cell
disease Transfusion-dependent beta thal****emia RVT-802
Enzyvant allogeneic cell
therapy Thymus tissue Congenital athymia in
DiGeorge syndrome...
- The
Scientist Magazine®.
Retrieved December 1, 2019. "Xconomy: Duke and
Enzyvant Take Rare
Immune Disease to
School with New Therapy". Xconomy.
March 5...
